Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458887 · ClinicalTrials.gov registry record
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
A clinical trial of Unspecified Childhood Solid Tumor, Protocol Specific and Ototoxicity, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 301
- Enrollment target
- 20
- Study locations
NCT00458887: Completed study of Unspecified Childhood Solid Tumor, Protocol Specific and Ototoxicity, sponsored by Children's Oncology Group.
NCT00458887 is a study of Unspecified Childhood Solid Tumor, Protocol Specific and Ototoxicity that has completed, run by Children's Oncology Group. The registered enrollment target is 301 participants, below the 1,614-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00458887, a study of Unspecified Childhood Solid Tumor, Protocol Specific and Ototoxicity, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 301 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.
Conditions Studied
Interventions
- PROCEDURE management of therapy complications
Study Locations (20)
Florida
- Lee Cancer Care of Lee Memorial Health System - Fort Myers
- Nemours Children's Clinic - Jacksonville
- University of Miami Sylvester Comprehensive Cancer Center - Miami - Miami
- Florida Hospital Cancer Institute at Florida Hospital Orlando - Orlando
- Nemours Children's Clinic - Orlando - Orlando
- Nemours Children's Clinic - Pensacola - Pensacola
- All Children's Hospital - St. Petersburg
- St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa
California
- Childrens Hospital Los Angeles - Los Angeles
- Southern California Permanente Medical Group - Los Angeles
- Children's Hospital Central California - Madera
- Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
- Rady Children's Hospital - San Diego - San Diego
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Connecticut
- Connecticut Children's Medical Center - Hartford
- Yale Cancer Center - New Haven
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Delaware
- Alfred I. duPont Hospital for Children - Wilmington
Hawaii
- Cancer Research Center of Hawaii - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2007-05 |
| Est. Completion | 2017-02-28 |
What the finished NCT00458887 record still lists
NCT00458887 is an observational study that tracks outcomes without assigning an intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 1,614-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which management of therapy complications is the first listed.
NCT00458887 names 20 study sites across 7 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00458887 about?
NCT00458887 is a clinical study titled "Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin". RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.
What is the current status of trial NCT00458887?
This trial is currently completed. The enrollment target is 301 participants. The study started on 2007-05. Estimated completion is 2017-02-28.
What conditions does trial NCT00458887 study?
This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific, Ototoxicity.
What interventions are being tested in trial NCT00458887?
The interventions under investigation include: management of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00458887?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00458887 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Childhood Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00458887's enrollment target sits among peer trials
301 3rd of 13 higher than 11 of 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Childhood Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
RECRUITING
-
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
COMPLETED · Phase 2
-
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
COMPLETED · Phase 1
-
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
COMPLETED · NA
-
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia